Posted by Michael Wonder on 05 Sep 2022
International work-sharing - first medicines approved by all five Access Consortium regulators
2 September 2022 - The TGA has approved two new medicines as part of the Access New Active-Substance Work-Sharing Initiative.
The two medicines are:
- Asciminib hydrochloride (Scemblix) - chronic myeloid leukaemia
- Faricimab (Vabysmo) - neovascular (wet) age-related macular degeneration and macular oedema
